On­coSec’s de­fense of weak pre­lim­i­nary Ta­vo da­ta for PD-1 re­sis­tant melanoma can’t stop a rout

On­coSec ex­ecs may be re­gret­ting their de­ci­sion to re­lease pre­lim­i­nary Phase IIb da­ta on the com­bi­na­tion of Mer­ck’s Keytru­da and their big pipeline play Ta­vo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER